ATNM News and Press, Actinium Pharmaceuticals Inc. From 04/12/22

Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...

Clinical-stage biotech Actinium Pharmaceuticals (NYSE:ATNM) and Swedish pharma group, Immedica Pharma AB announced an agreement for Iomab-B, a drug combination being developed for targeted conditioning in bone marrow transplant and other cell and gene therapies. The news of the license and su...

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa PR Newswire -Potential for up to $452 million in milestone payments with royalties in the mid-twenty percent ...

Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR PR Newswire - Data show enhanced antitumor effects and improved survival were observed in a preclinical NSCLC model compared to a naked HER3 antibody - HER3 targete...

Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect PR Newswire Data further expand Actinium's leadership in combining targeted radiotherapy with C...

ATNM has been running the SIERRA trial forever. They are promising TLD this year. Maybe the waiting will finally be over. For further details see: Actinium: Promises, Promises

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors - Actinium to apply its proprietary Antibody Warhead Enabling (AWE) technology platform to perform conjuga...

The following slide deck was published by Actinium Pharmaceuticals, Inc. in conjunction with this event. For further details see: Actinium Pharmaceuticals, Inc. (ATNM) Investor Presentation - Slideshow

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy - Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of t...

ATNM came out with excellent BMT engraftment data at ASH. The molecule performs better than standard, non-targeted conditioning regiments both in terms of safety and efficacy. ATNM is trading near 52-week lows. For further details see: Actinium: SIERRA Is Progressing Wel...